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Over the past three decades a series of discoveries in the specialty of ophthalmology have been 
central to furthering the understanding of genetic disease. However, currently ophthalmic 
genomics is seen as a niche area practised by a small number of highly trained experts; but things 
are changing. As part of the NHS England Long Term plan there is now a major initiative to 
develop personalised approaches to medicine with delivery of 500,000  individuals offered whole 
genome sequencing by 2023 (1). As such, genomic testing in ophthalmology is due to change 
significantly with the introduction of a national directory of approved genetic tests, three 
appointed laboratory providers of specialised ophthalmic genomic testing and importantly, 
centralised funding for most rare disease testing. The other three home nations are also at 
advanced stages of planning in this area. Therefore, now is an opportune time to consider how to 
integrate genomics into mainstream ophthalmic practice. 
A wide range of discoveries – from rare to common 
It is perhaps ironic that genetic discoveries within ophthalmology have become so frequent and 
so numerous that we downplay their clinical significance and treat them as commonplace. From 
rare disease to common, from cancer to neuro-degeneration, they are quite the reverse. 
Retinoblastoma, the paradigm for understanding tumour suppressor gene mutation, is a 
rare, familial and, let us not forget, lethal cancer-predisposing condition. It should not be 
underestimated that, for most of those provided with an early genetic diagnosis and 
specialist therapeutic intervention, retinoblastoma has become curable in most Western 
countries.   
Inherited retinal diseases (IRD) are now known to be a group of staggering breadth and 
heterogeneity. The sheer length of the list of gene discoveries makes the eyes, of even the 
most hardened super-specialist, glaze over. Recent ground-breaking publications show that 
successful, targeted interventions are, at last, becoming available. Treatment trials of 
potential therapies ranging from conventional drugs (for Leber Hereditary Optic 
Neuropathy; LHON) to gene replacements (CHM, RPE65); and antisense technologies (for 
Leber congenital amaurosis; LCA) represent an extraordinary potential turnaround for 
groups of patients who were told, until recently, that there is ‘nothing we can do’ (2-3)   
There will be those who argue that genetic discoveries will never have true impact until 
they apply to conditions affecting more than 2 in 10,000 individuals, a frequency below 
which a disease is defined as rare - although 17 million individuals, the number of patients 
in the UK with rare diseases, might take exception to this view. However genetics is directly 
relevant to our commonest diseases. Progress in unravelling the genetic aetiology of age-
related macular disease, the commonest reason for visual impairment registration in the 
UK, is now far advanced and probably ahead of any other common / ‘polygenic’ / complex 
genetic disorders. This has shown how complement dysregulation results in localised 
macular inflammation which has now started to lead to novel treatment approaches. 
 
Important yet often undervalued. Why? 
Currently these discoveries feel beyond the reach of, and more crucially of little help to, the 
mainstream ophthalmologist. To the busy clinician genetic advances have perhaps reasonably 
carried a strong scent of ‘So What?’. As a consequence, few patients with genetic disease receive 
a molecular diagnosis, few clinicians know patients who have received a gene-based diagnosis, 
and fewer still will, themselves, have ever ordered a genetic test. Yet it is likely that all will know 
patients affected by genetic eye disease.  
Why the disconnect? In large part, this has been due to the difficulty in reliably getting genetic 
diagnoses via molecular testing. Prior to this year, UK genetic testing budgets were held outside 
of ophthalmology and this often resulted in case by case assessments to justify testing. This 
required specialist knowledge and made it challenging for many to order and fund genomic 
testing, resulting in little or no testing within the context of the NHS system. This is now changing 
(figure 1). 
 
Key changes to the structure of Genomic Medicine Delivery in England  
that will impact on Ophthalmology: 
 
1. Centralised funding for rare disease testing. Any patient for whom a test is indicated is 
eligible to be tested. The ordering clinician does not need to pay for the test, which is 
budgeted centrally by NHSE. 
Alongside this are two other changes that will facilitate ordering 
2. A directory of genetic tests that defines a comprehensive range of conditions for which 
specific tests are now available. 
 
3. The creation of three testing laboratories for ophthalmic genetics, allowing the 
development of clinical (multidisciplinary management and reporting) structures to support 
test ordering and interpretation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: National changes in Genomic Medicine and the creation of A National Genomic 
Medicine Service.  
Two things are happening that should make us stand up and take note.  
The first is a rapid change in genomic diagnostic technologies, with evidence that they are cost 
effective. Until very recently, technological limitations meant that genetic testing was possible 
for only a tiny minority of rare conditions, at high cost. However, the ability to sequence large 
portions of an individual’s DNA at the same time (‘massively parallel sequencing’) – indeed to 
undertake whole genome sequencing (WGS) – means that, for rare diseases, as well as for many 
tumour types, molecular analysis is now possible at a price hitherto unimaginable (the 
sequencing of a whole genome is currently estimated to cost about £1000).  
The second is a change to health budgets and a re-organisation of genetic services. NHS England 
has undertaken a landmark revamp of the supporting infra-structure and the other home nations 
are similarly engaged in providing new services with variations in funding and hub models (4). 
There are three key elements in England listed in Figure 1. They include centralised funding for 
rare disease testing, a novel genomic test directory (Figure 2) and the creation of seven 
laboratories (‘Genomic Laboratoryr Hubs’) to provide support for NHS testing – of which three 
will undertake testing of ophthalmic genetic conditions. As a consequence, molecular genetic 
testing is both possible and affordable within structures in place to deliver it. It is fair to say that 
this creates a unique and national genomic medicine service that offers considerable 
opportunity. The education of all health care staff in genomics and set up of clinical pathways 
regionally will secure the future of this benefit to patients.  
  
 
 
 
Lens disorders including 
Bilateral congenital or childhood onset cataract; Lens subluxation 
Inherited Retinal disorders including  
Macular dystrophy; rod cone and cone rod dystrophy; Bardet Biedl syndrome 
X-linked retinitis pigmentosa  
Structural eye disease including  
anophthalmia / microphthalmia / coloboma 
childhood glaucoma 
anterior segment dysgenesis 
Aniridia  
Albinism or congenital nystagmus  
Optic neuropathy  
Congenital fibrosis of the extraocular muscles  
Corneal clouding and corneal dystrophy  
Stickler syndrome  
 
 
Figure 2:  Diagnostic testing for rare ophthalmic disorders using genomic approaches including 
gene panels, whole exome and whole genome sequencing 
Why does this matter -  and to whom?  
First, this matters to patients. Patients with rare diseases seek testing to provide closure and 
complete their search for a diagnosis - ending their so-called ‘diagnostic odyssey’. Patients 
correctly see this helping with clinical decision-making, better understanding of their prognosis 
and defining if there are any current, or future, therapeutic options available to them. However a 
clear diagnosis also helps with coping, adjustment, understanding family risks and emotional 
preparation for family members.  
Second, this matters to clinicians and providers of health care. Efficient testing can save both the 
time and costs that result from the ordering of multiple expensive (usually negative) and 
consecutive diagnostic investigations, a situation that is common for patients with complex / rare 
disease. The consequence of these inefficiencies, and what is often acutely felt by patients with 
rare disorders, is the exacerbation of disease burden through delayed diagnosis, inaccurate 
management, inappropriate appointments and incorrect referral into specialist care. 
Lastly, it is likely that this will improve equity of access. Since specialist care has often developed 
in a piecemeal manner based upon an individual clinician’s special interests, those with rare 
diseases are more likely to be diagnosed if they see - or live close to - a clinician who happens to 
recognise that condition or to have seen it before. That is, access to specialist care has a strong 
dependence on luck. Removing the physical barrier that resulted from an inability to provide and 
pay for genomic testing has the potential to ensure that any patient who can benefit from such 
testing (i.e. get a diagnosis) is able to access it.  
Now is the time to get involved  
The necessary structures have been developed to make genomic testing more widely available. 
In the first instance, this will make existing clinical pathways smoother, particularly for 
individuals with inherited paediatric disorders (e.g. congenital cataract; early-onset nystagmus, 
lens dislocation, macular dystrophy, optic neuropathy), adult retinal conditions and for those 
with rare diseases, genomic testing is likely to be performed earlier in the care pathway and 
become an integral part of diagnosis and management. 
However, the stated aim is to widen access to genetic testing to more patients by encouraging its 
use by a broader group of clinicians that sit outside those few experts currently ‘in the know’. It is 
important to remember that all ophthalmic clinicians see patients with rare diseases as well as 
common conditions with genetic causes or influences. Indeed, most rare ophthalmic conditions 
are first seen by general ophthalmologists. Thus, it is vital that all ophthalmologists are aware of 
and become part of the roll out of the new system so that  there will be accelerated diagnosis, 
improved access to novel therapies and streamlined care.  
It will, therefore, be critical that those undertaking the testing are provided with the clearest 
understanding of firstly, how such tests may be ordered, with access to appropriate training, and 
secondly how they may return results to patients safely and with confidence.  Education and 
training packages as well as defined pathways of care that have the multidisciplinary support of 
clinical geneticists and genomic counsellors (infrastructure support) are being developed to this 
end. The development of local, regional and national clinical networks, using precise 
multidisciplinary care approaches to work within the new genomic medical service is underway. 
It is essential that all clincians are aware of the existence of this infra-structure and that support 
is available to deliver this care to the patients who will benefit from it. 
However there is a second imperative that sits within the clinical specialties. Genomics has 
always been seen as sitting somewhat aloof, making it easy for the generalist to ignore.  As this 
changes and it moves closer to the heart of mainstream medicine in all specialities, this approach 
will become unjustifiable. The shift in emphasis – the so-called ‘mainstreaming’ of genomic 
medicine - will require supporting a motivated ophthalmic workforce to truly integrate genomics 
into ophthalmology. The national changes in genomic testing represent a great opportunity to 
provide better integrated care for our patients which we must embrace as ophthalmologists. 
Resources already exist to improve our understanding of genomics and the Royal College of 
Ophthalmologists is currently reviewing how it can provide more genomic resources and training 
for its members (5,6). 
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